N-terminally modified GLP-1 receptor modulators

Details for Australian Patent Application No. 2006249869 (hide)

Owner Bristol-Myers Squibb Company

Inventors Ewing, William R.; Riexinger, Douglas James; Sulsky, Richard B.; Mapelli, Claudio; Lee, Ving G.; Zhu, Yeheng

Agent A J Park

Pub. Number AU-A-2006249869

PCT Pub. Number WO2006/127948

Priority 60/684,805 26.05.05 US

Filing date 26 May 2006

Wipo publication date 30 November 2006

International Classifications

C07K 14/605 (2006.01) Peptides having more than 20 amino acids

C07K 7/06 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

Event Publications

6 December 2007 PCT application entered the National Phase

  PCT publication WO2006/127948 Priority application(s): WO2006/127948

27 May 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006249874-Echogenic microbubbles and microemulsions for ultrasound-enhanced nanoparticle-mediated delivery of agents

2006249868-Evolutionary synthesis of a modem for band-limited non-linear channels